Vaccine side effects should be viewed as a sign of efficacy, say immunologists

The rapid development of safe and efficacious vaccines against SARS-CoV-2 has offered hope that the global COVID-19 pandemic may soon be under control. However, vaccinations remain incomplete in many developed nations, and lag further still in the developing world.

In a new Focus, Jonathan Sprent and Cecile King posit that vaccine hesitancy, motivated in part by fear of side effects documented in scientific journals and the popular media, could hold back the global population from reaching herd immunity.

Seeking to reassure those with reservations, Sprent and King suggest that "it is highly likely - albeit not proven - that the side effects of COVID-19 vaccines are simply a by-product of a short burst of [type I interferon] generation concomitant with induction of an effective immune response."

Thus, they contend that "the prospect of fatigue and headache after vaccination for COVID-19 should be viewed positively: as a necessary prelude to an effective immune response."

Source:
Journal reference:

Sprent, J & King, C., (2021) COVID-19 vaccine side effects: The positives about feeling bad. Science Immunology. doi.org/10.1126/sciimmunol.abj9256.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine